Similarities and Differences Between HFmrEF and HFpEF
Open Access
- 20 September 2021
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
Abstract
The new guidelines classify heart failure (HF) into three subgroups based on the ejection fraction (EF): HF with reduced EF (HFrEF), HF with mid-range EF (HFmrEF), and HF with preserved EF (HFpEF). The new guidelines regarding the declaration of HFmrEF as a unique phenotype have achieved the goal of stimulating research on the basic characteristics, pathophysiology, and treatment of HF patients with a left ventricular EF of 40–49%. Patients with HFmrEF have more often been described as an intermediate population between HFrEF and HFpEF patients; however, with regard to etiology and clinical indicators, they are more similar to the HFrEF population. Concerning clinical prognosis, they are closer to HFpEF because both populations have a good prognosis and quality of life. Meanwhile, growing evidence indicates that HFmrEF and HFpEF show heterogeneity in presentation and pathophysiology, and the emergence of this heterogeneity often plays a crucial role in the prognosis and treatment of the disease. To date, the exact mechanisms and effective treatment strategies of HFmrEF and HFpEF are still poorly understood, but some of the current evidence, from observational studies and post-hoc analyses of randomized controlled trials, have shown that patients with HFmrEF may benefit more from HFrEF treatment strategies, such as beta-blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, mineralocorticoid receptor antagonists, and sacubitril/valsartan. This review summarizes available data from current clinical practice and mechanistic studies in terms of epidemiology, etiology, clinical indicators, mechanisms, and treatments to discuss the potential association between HFmrEF and HFpEF patients.Keywords
Funding Information
- National Natural Science Foundation of China
- Guangzhou Municipal Science and Technology Project (201804010086)
This publication has 131 references indexed in Scilit:
- Cardiac Metabolism in Heart FailureCirculation Research, 2013
- Deranged myofilament phosphorylation and function in experimental heart failure with preserved ejection fractionCardiovascular Research, 2012
- ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESCEuropean Heart Journal, 2012
- Glycotoxin and Autoantibodies Are Additive Environmentally Determined Predictors of Type 1 DiabetesDiabetes, 2012
- Abnormal haemodynamic response to exercise in heart failure with preserved ejection fractionEuropean Journal of Heart Failure, 2011
- Determinants of Exercise Intolerance in Elderly Heart Failure Patients With Preserved Ejection FractionJournal of the American College of Cardiology, 2011
- Soluble Guanylate Cyclase as an Emerging Therapeutic Target in Cardiopulmonary DiseaseCirculation, 2011
- Cardiac mitochondria in heart failure: decrease in respirasomes and oxidative phosphorylationCardiovascular Research, 2008
- Recruitment of Compensatory Pathways to Sustain Oxidative Flux With Reduced Carnitine Palmitoyltransferase I Activity Characterizes Inefficiency in Energy Metabolism in Hypertrophied HeartsCirculation, 2007
- Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol LevelsThe New England Journal of Medicine, 1998